Pneumagen is using its platform technology, GlycoTarge, to develop glycan targeted carbohydrate-binding module domains (mCBMs) derived from bacterial glycosidases as a new universal therapeutic modality for the prevention and treatment of respiratory tract infections (RTIs). These engineered mCBMs have been shown to prevent and treat respiratory infections by binding to epithelial cell surface glycan receptors present in the respiratory tract, used by several pathogens for entry.
Pneumagen’s lead product, Neumifil, is a first-in-class mCBM40 being developed for the universal treatment of Influenza Virus (IFV), Respiratory Syncytial Virus (RSV), and coronavirus COVID-19 infections. When administered intranasally in preclinical models, Neumifil has demonstrated prevention, treatment and post-exposure prophylaxis of IFV and RSV infection with no observed toxicity. Pneumagen’s mCBMs, in development for cancer, are known as Neumonco. In vitro data have demonstrated that mCBMs target cancer cells, reducing cell proliferation, migration, metabolism and differentiation.
The Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
Please visit www.pneumagen.com for more information.”
Pneumagen’s lead product, Neumifil, is a first-in-class mCBM40 being developed for the universal treatment of Influenza Virus (IFV), Respiratory Syncytial Virus (RSV), and coronavirus COVID-19 infections. When administered intranasally in preclinical models, Neumifil has demonstrated prevention, treatment and post-exposure prophylaxis of IFV and RSV infection with no observed toxicity. Pneumagen’s mCBMs, in development for cancer, are known as Neumonco. In vitro data have demonstrated that mCBMs target cancer cells, reducing cell proliferation, migration, metabolism and differentiation.
The Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
Please visit www.pneumagen.com for more information.”
Location: United Kingdom, Scotland
Total raised: $13.52M
Investors 2
| Date | Name | Website |
| - | Esperante | esperante.... |
| - | GIL Invest... | gilinvest.... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 19.01.2022 | - | $5.18M | - |
| 21.01.2021 | - | $3.43M | - |
| 27.05.2020 | - | $4.91M | - |
Mentions in press and media 6
| Date | Title | Description |
| 01.06.2023 | Pneumagen raises £8m to accelerate Phase 2 clinical development of Neumifil for the prevention & treatment of viral respiratory tract infections | - |
| 19.01.2022 | Pneumagen Raises £3.8M in Funding | Pneumagen, a St. Andrews, Scotland, UK-based clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), raised a further £3.8m in fund... |
| 21.01.2021 | Pneumagen Raises Further GBP2.5M in Funding | Pneumagen Ltd, a St Andrews, Scotland, UK-based company focused on preventing and treating respiratory infections by targeting the human glycome, raised a further GBP2.5m in funding. Backers included existing investors plus a new undisclose... |
| 27.05.2020 | Pneumagen Raises £4M in Funding | Pneumagen (Holdings) Ltd, a St Andrews, Scotland, UK-based company focused on treating infectious diseases by targeting the human glycome, raised GBP £4m in funding. The round was led by Thairm Bio (Thairm) with participation from the Scott... |
| 28.04.2020 | Pneumagen Ltd Announces Positive Anti-Viral Activity for Novel Glycan Approach in Preventing Coronavirus (COVID-19) Infections | |
| - | Pneumagen | “Pneumagen” |